Company News

• Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

  2019 / 09 / 03

  Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis FOSTER CITY, Calif.--Jul. 19, 2019--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

• Merck Potential met New Drug for Lung Cancer Submitted to ind China

  2019 / 08 / 28

  .Tepotinib film officially submitted a new drug IND in China: Tepotinib tablets are an oral MET inhibitor. Preclinical data show that Tepotinib can overcome the acquired resistance to EGFR-TKI due to abnormal MET activation, and theoretically improve the efficacy of patients with MET-positive EGFR-TKI-resistant NSCLC. Note: MET positive generally refers to MET overexpression and / or MET gene amplification Wherein MET overexpression is defined as immunohistochemistry IHC 2-3+; MET gene amplification is defined as in situ hybridization (ISH) detection of gene copy number (GCN) ≥ 5 and or MET / CEP7 ≥ 2.

• Xtandi successful in prostate cancer Phase III trial

  2019 / 03 / 13

  Pfizer and Astellas have announced results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi (enzalutamide) significantly improved radiographic progression-free survival, paving the way for an application to expand the drug's use. (Enzalutamide news, Enzalutamide intermediates) The results, which are for the drug in combination with androgen deprivation therapy, show a significant reduction in the risk of radiographic progression or death by 61%, thus meeting the trial's primary endpoint. The companies say they intend to discuss the data with global health authorities to potentially support a new indication for XTANDI in men with mHSPC. [The ARCHES trial demonstrated that Xtandi plus standard hormonal therapy delayed disease progression, and if approved, has the potential to be an important treatment option for men with prostate cancer that has spread but has not yet become hormone resistant," said Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology, and director of research in the Duke Cancer Institute`s Center for Prostate and Urologic Cancers.